

1 **Direct Observation of the Mechanism of Antibiotic Resistance by Mix-and-Inject at the**
2 **European XFEL**

3
4 Suraj Pandey¹, George Calvey², Andrea M. Katz², Tek Narsingh Malla¹, Faisal H. M. Koua³, Jose
5 M. Martin-Garcia^{4,5}, Ishwor Poudyal¹, Jay-How Yang⁴, Mohammad Vakili⁶, Oleksandr Yefanov³,
6 Kara A. Zielinski², Saša Bajt^{7,8}, Salah Awel³, Katerina Dörner⁶, Matthias Frank⁹, Luca Gelisio³,
7 Rebecca Jernigan⁴, Henry Kirkwood⁶, Marco Kloos⁶, Jayanath Koliyadu⁶, Valerio Mariani³,
8 Mitchell D. Miller¹⁰, Grant Mills⁶, Garrett Nelson¹¹, Jose L. Olmos Jr.¹⁰, Alireza Sadri³, Tokushi
9 Sato⁶, Alexandra Tolstikova³, Weijun Xu¹⁰, Abbas Ourmazd¹, John H. C. Spence¹¹, Peter
10 Schwander¹, Anton Barty⁷, Henry N. Chapman^{3,8,12}, Petra Fromme⁴, Adrian P. Mancuso^{6,13},
11 George N. Phillips Jr.^{10,14}, Richard Bean⁶, Lois Pollack², Marius Schmidt^{1,#}.

12
13 1. Physics Department, University of Wisconsin-Milwaukee, 3135 N. Maryland Ave,
14 Milwaukee, Wisconsin 53211, USA

15 2. School of Applied and Engineering Physics, Cornell University, 254 Clark Hall,
16 Ithaca, New York 14853, USA

17 3. Center for Free-Electron Laser Science, Deutsches Elektronen Synchrotron, Notkestrasse 85,
18 22607 Hamburg, Germany

19 4. School of Molecular Sciences and Biodesign Center for Applied Structural Discovery,
20 Arizona State University, Tempe, AZ 85287-1604, USA

21 5. present address: Institute Physical-Chemistry Rocasolano, Spanish National Research Council,
22 Serrano street 109, 28006, Madrid, Spain

23 6. European XFEL GmbH, Holzkoppel 4, 22869 Schenefeld, Germany

24 7. Deutsches Elektronen Synchrotron, Notkestrasse 85, 22607 Hamburg, Germany

25 8. The Hamburg Centre for Ultrafast Imaging, Luruper Chaussee 149, 22761 Hamburg, Germany

26 9. Lawrence Livermore National Laboratory, 7000 East Avenue, Livermore, CA 94550, USA

27 10. Department of BioSciences, Rice University, 6100 Main Street, Houston, Texas 77005, USA

28 11. Department of Physics, Arizona State University, Tempe, Arizona 85287, USA

29 12. Department of Physics, Universitaet Hamburg, Luruper Chaussee 149, 22761 Hamburg,
30 Germany

31 13. Department of Chemistry and Physics, La Trobe Institute for Molecular Science, La Trobe
32 University, Melbourne, Victoria 3086, Australia

33 14. Department of Chemistry, Rice University, 6100 Main Street, Houston, Texas 77005, USA

34

35 # Corresponding author: m-schmidt@uwm.edu

36

37 **Abstract**

38 In this study, we follow the diffusion and buildup of occupancy of the substrate ceftriaxone
39 in *M. tuberculosis* β -lactamase BlaC microcrystals by structural analysis of the enzyme substrate
40 complex at single millisecond time resolution. We also show the binding and the reaction of an
41 inhibitor, sulbactam, on a slower millisecond time scale. We use the ‘mix-and-inject’ technique to
42 initiate these reactions by diffusion, and determine the resulting structures by serial crystallography
43 using ultrafast, intense X-ray pulses from the European XFEL (EuXFEL) arriving at MHz
44 repetition rates. Here, we show how to use the EuXFEL pulse structure to dramatically increase
45 the size of the data set and thereby the quality and time resolution of “molecular movies” which
46 unravel ligand binding and enzymatically catalyzed reactions. This shows the great potential for
47 the EuXFEL as a tool for biomedically relevant research, particularly, as shown here, for
48 investigating bacterial antibiotic resistance.

49

50 **One Sentence Summary**

51 Direct observation of fast ligand binding in a biomedically relevant enzyme at near atomic
52 resolution with MHz X-ray pulses at the European XFEL.

53

54

55

56 Combatting the rise of infectious diseases requires a collaborative and interdisciplinary
57 approach. Structural biologists can contribute by investigating the reaction mechanisms of
58 biomedically significant enzymes as a structural basis to develop cures for diseases. Bacterial
59 infections with strains that are resistant to currently available antibiotics are on the rise (1). A study
60 sponsored by the British government projected that in the near future more people will die from
61 untreatable bacterial infections than from cancer (<https://amr-review.org/>). Bacterial enzymes that
62 inactivate currently available drugs are central to antibiotic resistance (2) and unraveling the
63 catalytic mechanism of these enzymes will be beneficial for the development of novel antibiotics
64 (3). β -lactamases such as *M. tuberculosis* β -lactamase (BlaC), catalytically inactivate β -lactam
65 antibiotics and are responsible for the emergence of multidrug and extensively drug resistant
66 bacterial strains(4). Infectious diseases that could be treated with β -lactam antibiotics in the past
67 may become untreatable.

68 With time-resolved crystallography, structures of intermediates and kinetic mechanisms
69 can be extracted simultaneously from the same set of X-ray data (5, 6). Pioneering time-resolved
70 crystallographic experiments at XFELs were all of the pump-probe type, where an optical laser
71 pulse triggers a reaction in the crystallized molecules which are probed by x-ray pulses after a
72 controlled delay (7, 8), with experiments capable of reaching sub-ps time resolutions (9, 10).
73 Photoactivation, however, requires a light sensitive cofactor, a chromophore, located in the protein
74 of interest to absorb the light. For investigating reactions in enzymes, this light absorption must
75 trigger a reaction that either promotes catalysis directly (11) or adjusts the activity of the enzyme
76 (12-14). Most enzymes, however, are neither activated nor regulated by light, meaning the
77 technique can only be directly applied in a narrow range of cases. Broader application requires
78 great effort and chemical expertise to either engineer photoactive enzymes or to design photoactive
79 compounds that can be soaked into, and activated in, enzyme crystals (15, 16).

80 With the ‘mix-and-inject’ technique (17-20) photoactivation is not necessary. Substrate is
81 rapidly mixed with small enzyme crystals during sample delivery (21). Mixing occurs at a well-
82 controlled location ‘en route’ to the X-ray beam. During the time-delay ΔT_{mi} that occurs between
83 mixing and injection, substrate diffuses into the crystals and binds to the enzyme. The complex
84 formed by the substrate and the enzyme then initiates the enzymatic cycle. Variation of ΔT_{mi} allows
85 measurement of chemical rate coefficients, and can associate an atomic-resolution structure to
86 intermediate states which occur during protein reactions. This can reveal the mechanism of enzyme

87 action at the molecular level, or the binding of a drug molecule. The feasibility of the mix-and-
88 inject technique on enzymes was first demonstrated with the BlaC on longer millisecond
89 timescales (18, 19). The observation of intermediate state structures, and maximization of the
90 potential time resolution in both photoactivation and mix-and-inject techniques, relies on an
91 accurately gauged start time of the reaction inside the crystals. In photoactivation experiments this
92 requires a sufficient penetration of an optical laser into the crystal to ensure a reaction is
93 simultaneously triggered in a significant fraction of the molecules. The laser power, however, must
94 be carefully adjusted to avoid multi-photon excitation pathways and damage (22, 23). In mix-and-
95 inject experiments, the diffusion time of substrate into the crystal limits the ability to discriminate
96 diffusion and kinetics, including substrate binding. In both cases these considerations require
97 micron or sub-micron crystal sizes, with limited scattering power.

98 At X-ray Free Electron Lasers (XFELs) small, micrometer (μm) and sub- μm sized, crystals
99 can be examined due to the immense X-ray pulse intensity (24). Micro-crystals are destroyed by
100 the pulses, and new crystals must be delivered to the X-ray interaction point in a serial fashion
101 (25). Since the XFEL pulses are of femtosecond duration, diffraction patterns are collected before
102 the crystals suffer significant radiation damage, resulting in X-ray structures that are essentially
103 damage-free (26, 27) and suspended in their current reaction state. The combination of serial
104 femtosecond crystallography (SFX) (24, 25) with mixing before injection has been denoted ‘Mix-
105 and-Inject Serial Crystallography’ (MISC) (18-20).

106 The BlaC reaction with the cephalosporin antibiotic CEF is an excellent candidate for
107 exploration with MISC. Previously, this reaction was investigated for ΔT_{mi} longer than 30 ms (18,
108 19). At 30 ms, however, the CEF binding sites in BlaC were essentially fully occupied (19), a
109 state also reached on similar time-scales for other proteins and enzymes (20, 28, 29). The important
110 substrate binding phase and the formation of the enzyme-substrate complex, however, remain
111 elusive.

112 **Mix-and-Inject Experiments at the EuXFEL**

113 To observe substrate binding directly, we performed a pioneering single ms MISC
114 experiments at the SPB/SFX instrument(30) of the superconducting European XFEL (EuXFEL)
115 in Germany(31). Here, we used the EuXFEL MHz pulse structure(8) to measure the binding of the
116 large CEF substrate to BlaC on timescales much faster than 30 ms to capture diffusion and the
117 binding kinetics. In addition, we investigated the reaction of the BlaC with an inhibitor, sulbactam

118 (SUB) on a millisecond time scale. The biochemistry of SUB and its application in combination
119 with β -lactam antibiotics are described in detail elsewhere (32). SUB binds to the active site of
120 BlaC and reacts with the catalytically active serine of β -lactamases to form various covalently
121 bound species. Most abundant is the so-called *trans*-enamine (*trans*-EN) species (Scheme S1,
122 compound III) that inhibits β -lactamases and helps to eliminate β -lactamase induced antibiotic
123 resistance. The static structures of *trans*-ENs with β -lactamases, including BlaC, were recently
124 characterized (33, 34) but structures of the early species that form during SUB binding remain
125 elusive.




Figure 1. The crystal structure of BlaC. (a) Sulbactam (SUB) binds to all four subunit (A-D) in the asymmetric unit. The phosphates in the active sites are not replaced. Isomorphous difference map (DED_{iso}) (2 sigma) shown in green. (b) Active site in subunit C with non-covalently bound intact sulbactam, left side: DED_{iso} map, right side: 2mFo-DFc map after refinement. Close by amino acids and the phosphate (P_i) are marked. (c) Active site in subunit B with *trans*-enamine bound to Ser-70, left side: DED_{iso} map, right side: 2mFo-DFc map after refinement. Red and blue dot show important differences between the subunits. Gln112 from the adjacent subunit is not located close-by, and the Arg173 is extended in subunit B leaving subunit B more accessible to ligands and substrate.

126 BlaC crystals grown with ammonium phosphate form platelet shaped microcrystals (Fig.
127 S1 a) which are ideal for mix-and-inject investigations on fast time scales. Fig. 1 a shows the
128 structure of the BlaC in this crystal form. A dense suspension of microcrystals was injected into
129 the $\sim 3 \mu\text{m}$ X-ray focus of the SPB/SFX instrument (30) of the EuXFEL (Fig. 2). For CEF, three
130 time delays ΔT_{mi} at 5 ms, 10 ms, and 50 ms were probed. The reaction of BlaC with SUB was
131 probed 66 ms after mixing. As a reference and a control the BlaC crystals were mixed with water

132 and probed 10 ms after mixing (see Table S1 for data statistics and Material and Methods for
133 further details).




Figure 2. Experimental setup at the European XFEL. Microcrystals are mixed with substrate, and injected into the X-ray after a delay determined by the distance between the mixing region and the X-rays, the capillary width, and the flow rate. Diffusion of substrate into the crystals occurs during this time. The mixture is probed by trains of X-ray pulses. The trains repeat 10 times per second. Pulses within the trains repeat with 564 kHz, hence the pulses are spaced by 1.78 μ s. 202 pulses were in each train for this experiment. The AGIPD collects the diffraction patterns and reads them out for further analysis. Insert, data collection: With a once selected injector geometry and flow rate, the delay is fixed by the distance of the mixing region from the X-ray interaction region. All pulses in all trains (here pulse #3) probe the same time delay. The EuXFEL pulse structure is most efficiently used.

134 **The Induced Fit: Formation of the Enzyme Substrate Complex**

135 Fig. 3 shows CEF binding. As observed in a previous study at the longer ΔT_{mi} of 2 s (18),
136 CEF binds only to subunits B and D. In Fig. 3 a, DED_{omit} in the active site of subunit B is shown.
137 On early time scales (5 ms and 10 ms after mixing) we observe a crystal-averaged electron density
138 of a CEF and a phosphate (P_i) molecule at this position. The P_i is also found near the CEF binding
139 site in the unliganded (unmixed) form. At a ΔT_{mi} of 50 ms, the P_i density has vanished.
140 Occupancies for P_i and CEF were refined using the program ‘Phenix’(35) at all ΔT_{mi} (Table S2).
141 At the 5 ms delay, the P_i and the CEF occupancies are both approximately 50 %. The available

142 catalytic sites in subunits B and D are equally occupied either by a CEF or by a P_i (Fig. 4 a). At
143 $\Delta T_{mi} = 50$ ms the P_i occupancy refines to 19 %, that of the CEF to 82 %. In agreement with previous
144 work(19), an additional CEF molecule is identified close to each active site that weakly interacts
145 (stacks) with the already bound CEF bound there (Fig. S2). The stacking sites are only transiently
146 visited by CEF molecules until the active sites are fully occupied. Unit cell parameter changes
147 roughly follow CEF binding and P_i release (Table S1, Fig. 4 a, insert). When the about 2.5 times
148 smaller sulbactam binds, the P_i is not replaced, and the unit cell parameters do not change (Table
149 S1). We postulate that the size of the ligand, as well as the displacement of the strongly negatively
150 charged P_i may contribute to the unit cell changes as observed when CEF is mixed in.




Figure 3. Omit difference electron density in the active center of BlaC, subunit B. (a) 5ms, (b) 10 ms after mixing and (c) 50 ms after mixing. Ser-70, CEF, the phosphate (P_i) and the water molecule are marked. The P_i is essentially absent in (c). Some nearby amino acids are displayed in addition.

151 As more CEF binds, Ser-70 moves towards the P_i position, and the P_i is replaced at the
152 same time (Table S3 c). Other amino acids such as Asn 172 and Asp 241 move closer to the CEF.
153 We can now develop a mini-movie for the formation of an enzyme-substrate (ES) complex. This
154 movie shows an induced fit (Supplementary Movie 1) and visualizes in real time how the active
155 site closes around the CEF. The induced fit phase finishes after $\Delta T_{mi} = 10$ ms when the CEF
156 occupancy approaches saturation. In the inactive subunits A and C, two glutamines, Gln-109 and
157 Gln-112, from adjacent, non-crystallographically related subunits, extend into the active sites and
158 would clash severely with the dioxo-triazine ring on one side and with the amino-thiazole ring on
159 the other side of CEF (Scheme S1, compound I), thus effectively preventing CEF binding.

160 The ES complex formation is most important since it triggers the enzymatic cycle. Hence,
161 it determines the time resolution of the MISC method. The ES complex consists of CEF non-
162 covalently bound in the active site of BlaC (Scheme S2). CEF is delivered by diffusion into the

163 crystals. Crystals must be small enough to enable short enough diffusion times, so that the binding
164 kinetics can be observed. However, MISC does not measure the free substrate concentration in the
165 crystals, and therefore diffusion is rather observed indirectly through the increase of occupancies
166 of well-ordered substrate molecules in the active centers of BlaC. When the diffusion times are
167 very short, occupancies may accumulate on a timescale longer than the diffusion time, as they are
168 governed by the binding kinetics. The ES complex formation is therefore not only dependent on
169 the ligand concentration delivered by diffusion but also on the magnitude of the rate coefficients
170 in the kinetic mechanism.




Figure 4. BlaC, CEF and the BlaC-CEF complex as a function of time. (a) Occupancies of CEF at 5 ms, 10 ms and 50 ms in subunits B (spheres) and D (squares) as well as those of phosphate (P_i) (green triangles and blue diamonds) are plotted as a function of delay. The data are fitted with saturation curves (eqs. S1 and S2, black and blue dashed lines). The two curves intersect at around 6 ms. Inset: corresponding change of unit cell axis c . (b) Concentrations (in %) as calculated from diffusion and binding (eqs. S1 - S5). Black spheres: increase of the free BlaC concentration, red squares: decrease of the free BlaC concentration, green triangles: increase of the BlaC-CEF complex concentration averaged over all voxels in the crystal, blue diamonds: increase of the BlaC-CEF complex in the center of the platelet shaped crystals. Data were fitted by saturation curves (corresponding black, red and green dashed lines). Concentrations in the crystal center (blue dashed line) were fitted by a logistic function.

171 On the short timescales employed here, the formation of later intermediates and the
172 catalytic turnover of the BlaC do not play a role. Both processes unfold over much longer
173 timescales than the time delays examined here (19). Diffusion follows Fick's 2nd law from whose
174 solution the CEF concentration can be estimated at any position in the crystal and at any time. CEF
175 binding to the active sites of BlaC is dependent on the free BlaC concentration in the crystal, the
176 CEF concentration and the rate coefficients that describe the kinetic mechanism. There is only one
177 free parameter, the diffusion coefficient D that can be inferred by matching calculated occupancies

Table 1. BlaC-CEF complex formation in microcrystals. Results from comparing observed and calculated occupancies.

BlaC-CEF increase		P _i decrease	BlaC-CEF in the crystal center		D for CEF	
observed*		observed*	sigmoidal increase**		water	D _{eff} ***
C _{s,cef}	τ _{1/2} [ms]	τ _{1/2} [ms]	k [ms ⁻¹]	t ₀ [ms]	[cm ² /s]	[cm ² /s]
88 %	4.6	6.7	0.2	15.5	2.3 x 10 ⁻⁶	2 x 10 ⁻⁷

*from saturation curves (eqs. S1 and S2), C_{s,CEF} is the saturation concentration of CEF, τ_{1/2} are characteristic times where 50 % of the final concentrations of CEF and phosphate are reached, respectively. **parameters of the logistics function (eq. S5) fitted to occupancies determined in the centers of the BlaC platelets.

***effective diffusion coefficient, from matching observed and calculated occupancies (see Methods).

178 to the occupancies measured at the ΔT_{mi} (compare Fig. 4 a and Fig. 4 b, see Methods for details).
179 CEF diffusion is about a factor of twelve slower (D_{eff} ~ 2 x 10⁻⁷ cm²/s) within the BlaC crystals
180 compared to water. This slowdown is in agreement with findings that were previously obtained
181 from simulations on substrate diffusion in enzyme crystals (36). Fig. 5 depicts the result of the
182 calculation. Estimates of enzyme-ligand occupancies are now directly deduced from time-resolved
183 X-ray crystallography everywhere in a crystal after mixing. Not surprisingly, at 5 ms the
184 occupancy is high (> 90 %) only near the crystal surface where enough substrate is present to
185 promote ES formation with a high rate. In the center of the crystals the ES complex concentration
186 is initially small (Fig. 4 b, Fig. 5 a). The binding rate is not sufficiently high to generate significant
187 occupancy. After ΔT_{mi} = 10 ms the binding rate increases, until at 30 ms full occupancy of the
188 BlaC-CEF complex is reached (Table S5 b and Fig. 4 b, green dashed line) everywhere. With the
189 rapid diffusion of CEF into small BlaC crystals we are now able to quantify variations of substrate,
190 enzyme and ES concentrations across the enzyme crystal volume (Table 1, Fig. 4 and Fig. 5). The
191 remarkable speed of the ES accumulation shows that the mix-and-inject technique can be used to
192 characterize enzymes with turnover times much faster than that of BlaC. The direct observation of
193 the important initial ligand and substrate binding phase in biomedically relevant enzymes is
194 possible.

195 Since the ES complex (here the BlaC-CEF complex) triggers the enzymatic cycle, accurate
196 kinetics can be extracted to the point that the time required to accumulate sufficient ES-complex
197 approaches the life-time of the next intermediate in the catalytic cycle (17). This finding holds for




Figure 5. Concentrations of the BlaC-CEF complex in $10 \times 10 \times 2 \mu\text{m}^3$ platelet shaped crystals, (a) 5 ms, (b) 10 ms, and (c) 30 ms after mixing with 200 mmol/L ceftriaxone (150 mmol/L final concentration assumed). The concentrations are shown in different colors (see scale bar on the right) in central cross sections through half the width of the crystals. The drawings are not to scale, since the sections displayed are $5 \mu\text{m}$ horizontally (width) and $2 \mu\text{m}$ vertically (thickness). The enlargement along the short $2 \mu\text{m}$ axis allows the display of nuanced occupancy differences.

198 any other technique (15) which aims to trigger enzymatic reactions, even in non-crystalline
199 samples. Not only it is required to bring enough substrate near the vicinity of the enzyme, but also
200 the binding kinetics needs to be taken into account. With microcrystals below a certain crystal size,
201 binding of substrate, and not the diffusion of substrate into the crystal volume, may become rate
202 limiting. As a consequence, for BlaC crystals about a size of $1 \mu\text{m}$, the speed of the ES complex
203 formation is not substantially different from that in solution. The D_{eff} determined here suggests
204 that accurate measurements of the substrate binding kinetics would not be possible with
205 significantly larger crystals. Enzymes with turnover times faster than the BlaC will usually also
206 display faster substrate binding kinetics with larger k_{on} rate coefficients. In such cases, the crystal
207 sizes (and their size distributions) or perhaps temperature must be adjusted appropriately to ensure
208 that the diffusion times can catch up with the substrate binding rates.

209 Inhibitor Binding and Reaction

210 SUB binds to all four subunits in the asymmetric unit, which is in stark contrast to CEF
211 that binds only to subunits B and D. Notably, however, the DED_{iso} is different for subunits A, C

212 and B, D. In subunits B and D, the electron density can be interpreted with a sulbactam *trans*-EN
213 covalently bound to Ser-70 (Scheme S1, compound III, Fig. 1 c, Table S2). The orientation of the
214 *trans*-EN in the active site is determined by residues Lys-73 and Thr-239 and in particular by Gln-
215 109 from the adjacent non-crystallographically related subunit (Table S3 b). In subunits A and C,
216 the DED_{iso} shows changes in a region more distant from Ser-70. Electron density details extend
217 from a spheroidal, central DED feature. An intact SUB molecule that is non-covalently bound to
218 the active site (Fig. 1 b, Scheme S1, compound II) can be fitted. The SUB is oriented so that the
219 ring sulfur-dioxide points towards Ser-70 with the β -lactam ring pointing away. We hypothesize
220 that this ‘up-side-down’ orientation is enforced by Arg-173 and Gln-112 (Table S3 a), where Gln-
221 112 is protruding deep into the active sites from the adjacent, non-crystallographically related
222 subunits (Fig. 1 b).

223 The diffusion time is fast enough that 66 ms after mixing all non-covalently bound SUB
224 molecules in subunits B and D have reacted to the covalently bound *trans*-EN. This is quite
225 unexpected as it was suggested that it would take minutes for the enamine to form after binding of
226 SUB in the BlaC (32-34). Although the SUB binds non-covalently to the active sites in subunits
227 A and C, the reaction with the Ser-70 did not occur within $\Delta T_{mi} = 66$ ms. It may be that SUB will
228 not react further in these subunits. It could also be that the structure of the BlaC-SUB complex is
229 an interesting intermediate on the reaction pathway to the *trans*-EN. Experiments exploring longer
230 ΔT_{mi} will clarify this situation. In subunits B and D Glu-112 is not near the active site, and Arg-
231 173 displays a stretched, open conformation allowing the SUB to orient correctly towards the Ser-
232 70, and to react further to the *trans*-EN that then non-competitively inhibits the BlaC (34). The
233 near-by P_i, which is displaced when the much larger ligand CEF is present, stays in place in all
234 subunits and likely adds to the stability of both complexes.

235 **Protein Dynamics at the EuXFEL**

236 In order to further investigate CEF and SUB binding and their reactions with Ser-70, a time
237 series should be collected that consists of datasets at multiple ΔT_{mi} that span from a few ms to
238 seconds. To achieve this, the EuXFEL pulse structure must be exploited most efficiently. Every
239 X-ray pulse in all pulse trains provides observations of the same time delay, and our experiments
240 took maximum advantage from the high pulse rate (Fig. 2, insert). This is in contrast to optical
241 pump-probe experiments that require appropriate waiting times between the laser excitations to
242 guarantee that the laser excited volume exits the X-ray interaction region, so that multiple laser

243 activations can be avoided (8). We showed that diffraction data sufficient for good quality structure
244 determination can be collected in about half an hour as demonstrated for the 50 ms CEF time point
245 (Table S4). This time can be reduced substantially by limiting the number of diffraction patterns
246 per dataset and by optimizing the crystal density flow through the mixing device. High crystal
247 density will lead to higher hit rates but might also causes frequent interruptions caused by injector
248 clogging. For our experiments, a fine balance between crystal size and crystal density was found
249 so that the mix-and-inject experiments with CEF and SUB could be completed successfully with
250 acceptable hit rates given the high X-ray pulse repetition rate at the EuXFEL. Previous experiments
251 have shown that the collection of sufficient patterns for structure determination should be possible
252 in less than 20 minutes at the detector-limited repetition rate of the EuXFEL (8, 37). This provides
253 the tantalizing possibility to directly characterize the kinetic processes in biomolecules from single
254 digit millisecond to longer time scales, within relatively short experimental times. The kinetics can
255 rapidly change when environmental conditions are varied. It may be possible, for example, to
256 control the temperature in the mixing injector delay line to determine barriers of activation from
257 the resulting X-ray data (38). The full analysis of such a multi-dimensional data set requires the
258 development and deployment of user-friendly classification algorithms to separate mixtures into
259 their pure components (39) and derive kinetics and energetics (38) consistent with the electron
260 density maps and structures of intermediate states along the reaction pathway.

261 Our experiments permitted a real-time view into the active sites of an enzyme during
262 substrate and inhibitor binding. They facilitate more mix-and-inject experiments at the EuXFEL
263 with unprecedented data collection rates allowing for more structures to be determined per
264 allocated experimental time. This capability will become an important tool for biomedically
265 relevant research in the years to come.

266 References

- 267 1. A. Cassini *et al.*, Attributable deaths and disability-adjusted life-years caused by
268 infections with antibiotic-resistant bacteria in the EU and the European Economic Area in
269 2015: a population-level modelling analysis. *Lancet Infect Dis* **19**, 56-66 (2019).
- 270 2. R. J. Fair, Y. Tor, Antibiotics and bacterial resistance in the 21st century. *Perspect*
271 *Medicin Chem* **6**, 25-64 (2014).
- 272 3. P. Imming, C. Sinning, A. Meyer, Drugs, their targets and the nature and number of drug
273 targets. *Nat Rev Drug Discov* **5**, 821-834 (2006).
- 274 4. T. Smith, K. A. Wolff, L. Nguyen, Molecular biology of drug resistance in
275 *Mycobacterium tuberculosis*. *Curr Top Microbiol Immunol* **374**, 53-80 (2013).

- 276 5. M. Schmidt, *Structure based enzyme kinetics by time-resolved X-ray crystallography*, in:
277 *ultrashort laser pulses in medicine and biology*. W. Zinth, M. Braun, P. Gilch, Eds.,
278 Biological and medical physics, biomedical engineering, ISSN 1618-7210 (Berlin ; New
279 York : Springer, c2008, Germany, 2008).
- 280 6. K. Moffat, Time-resolved biochemical crystallography: A mechanistic perspective.
281 *Chemical reviews* **101**, 1569-1581 (2001).
- 282 7. J. Tenboer *et al.*, Time-resolved serial crystallography captures high-resolution
283 intermediates of photoactive yellow protein. *Science* **346**, 1242-1246 (2014).
- 284 8. S. Pandey *et al.*, Time-resolved serial femtosecond crystallography at the European
285 XFEL. *Nature methods*, (2019).
- 286 9. K. Pande *et al.*, Femtosecond Structural Dynamics Drives the Trans/Cis Isomerization in
287 Photoactive Yellow Protein. *Science* **352**, 725-729 (2016).
- 288 10. T. R. Barends *et al.*, Direct observation of ultrafast collective motions in CO myoglobin
289 upon ligand dissociation. *Science*, (2015).
- 290 11. J. Li *et al.*, Dynamics and mechanism of repair of ultraviolet-induced (6-4) photoproduct
291 by photolyase. *Nature* **466**, 887-890 (2010).
- 292 12. E. Claesson *et al.*, The primary structural photoresponse of phytochrome proteins
293 captured by a femtosecond X-ray laser. *eLife* **9**, (2020).
- 294 13. H. Takala *et al.*, Signal amplification and transduction in phytochrome photosensors.
295 *Nature* **509**, 245-248 (2014).
- 296 14. G. Gourinchas *et al.*, Long-range allosteric signaling in red light-regulated diguanylyl
297 cyclases. *Sci Adv* **3**, e1602498 (2017).
- 298 15. V. Srajer, M. Schmidt, Watching proteins function with time-resolved x-ray
299 crystallography. *J Phys D Appl Phys* **50**, (2017).
- 300 16. J. J. Zaitsev-Doyle *et al.*, Synthesis and characterisation of alpha-carboxynitrobenzyl
301 photocaged l-aspartates for applications in time-resolved structural biology. *Rsc Adv* **9**,
302 8695-8699 (2019).
- 303 17. M. Schmidt, Mix and Inject, Reaction Initiation by Diffusion for Time-Resolved
304 Macromolecular Crystallography. *Advances on Condensed Matter Physics*, 1-10 (2013).
- 305 18. C. Kupitz *et al.*, Structural enzymology using X-ray free electron lasers. *Struct Dyn* **4**,
306 044003 (2017).
- 307 19. J. L. Olmos, Jr. *et al.*, Enzyme intermediates captured "on the fly" by mix-and-inject
308 serial crystallography. *BMC Biol* **16**, 59 (2018).
- 309 20. J. R. Stagno *et al.*, Structures of riboswitch RNA reaction states by mix-and-inject XFEL
310 serial crystallography. *Nature* **541**, 242-246 (2017).
- 311 21. G. D. Calvey, A. M. Katz, L. Pollack, Microfluidic Mixing Injector Holder Enables
312 Routine Structural Enzymology Measurements with Mix-and-Inject Serial
313 Crystallography Using X-ray Free Electron Lasers. *Anal Chem* **91**, 7139-7144 (2019).
- 314 22. C. D. M. Hutchison *et al.*, Photocycle populations with femtosecond excitation of
315 crystalline photoactive yellow protein. *Chem Phys Lett* **654**, 63-71 (2016).
- 316 23. M. L. Grunbein *et al.*, Illumination guidelines for ultrafast pump-probe experiments by
317 serial femtosecond crystallography. *Nature methods*, (2020).
- 318 24. S. Boutet *et al.*, High-resolution protein structure determination by serial femtosecond
319 crystallography. *Science* **337**, 362-364 (2012).
- 320 25. H. N. Chapman *et al.*, Femtosecond X-ray protein nanocrystallography. *Nature* **470**, 73-
321 77 (2011).

- 322 26. L. Lomb *et al.*, Radiation damage in protein serial femtosecond crystallography using an
323 x-ray free-electron laser. *Physical review. B, Condensed matter and materials physics* **84**,
324 214111 (2011).
- 325 27. K. Nass *et al.*, Indications of radiation damage in ferredoxin microcrystals using high-
326 intensity X-FEL beams. *J Synchrotron Radiat* **22**, 225-238 (2015).
- 327 28. P. Mehrabi *et al.*, Liquid application method for time-resolved analyses by serial
328 synchrotron crystallography. *Nature methods* **16**, 979-982 (2019).
- 329 29. I. Ishigami *et al.*, Snapshot of an oxygen intermediate in the catalytic reaction of
330 cytochrome c oxidase. *Proceedings of the National Academy of Sciences of the United*
331 *States of America* **116**, 3572-3577 (2019).
- 332 30. A. P. Mancuso *et al.*, The Single Particles, Clusters and Biomolecules and Serial
333 Femtosecond Crystallography instrument of the European XFEL: initial installation. *J.*
334 *Synchrotron Rad.* **26**, 660-676 (2019).
- 335 31. W. Decking *et al.*, A MHz-repetition-rate hard X-ray free-electron laser driven by a
336 superconducting linear accelerator (vol 14, pg 6311, 2020). *Nat Photonics*, (2020).
- 337 32. M. A. Totir *et al.*, Sulbactam forms only minimal amounts of irreversible acrylate-
338 enzyme with SHV-1 beta-lactamase. *Biochemistry* **46**, 8980-8987 (2007).
- 339 33. Q. Cheng *et al.*, Structural Insight into the Mechanism of Inhibitor Resistance in CTX-M-
340 199, a CTX-M-64 Variant Carrying the S(130)T Substitution. *ACS Infect Dis* **6**, 577-587
341 (2020).
- 342 34. R. Tassoni, A. Blok, N. S. Pannu, M. Ubbink, New Conformations of Acylation Adducts
343 of Inhibitors of beta-Lactamase from Mycobacterium tuberculosis. *Biochemistry* **58**, 997-
344 1009 (2019).
- 345 35. P. D. Adams *et al.*, PHENIX: a comprehensive Python-based system for macromolecular
346 structure solution. *Acta crystallographica. Section D, Biological crystallography* **66**, 213-
347 221 (2010).
- 348 36. S. Geremia, M. Campagnolo, N. Demitri, L. N. Johnson, Simulation of diffusion time of
349 small molecules in protein crystals. *Structure* **14**, 393-400 (2006).
- 350 37. O. Yefanov *et al.*, Evaluation of serial crystallographic structure determination within
351 megahertz pulse trains. *Struct Dyn-Us* **6**, (2019).
- 352 38. M. Schmidt *et al.*, Protein energy landscapes determined by five-dimensional
353 crystallography. *Acta crystallographica. Section D, Biological crystallography* **69**, 2534-
354 2542 (2013).
- 355 39. M. Schmidt, S. Rajagopal, Z. Ren, K. Moffat, Application of singular value
356 decomposition to the analysis of time-resolved macromolecular X-ray data. *Biophysical*
357 *journal* **84**, 2112-2129 (2003).

358

359

360 **Acknowledgements**

361 We are very grateful to those who supported this experiment by being present in person at the
362 European XFEL during the onset of the COVID-19 pandemic in March 2020. We acknowledge
363 the European XFEL in Schenefeld, Germany, for provision of X-ray free-electron laser beamtime

364 at scientific instrument SPB/SFX and would like to thank the staff for their assistance. This work
365 was supported by the National Science Foundation Science and Technology Center “BioXFEL”
366 through award STC-1231306, and in part by the US Department of Energy, Office of Science,
367 Basic Energy Sciences, under contract DE-SC0002164 (A.O., algorithm design and development)
368 and by the National Science Foundation under contract numbers 1551489 (A.O., underlying
369 analytical models) and DBI-2029533 (A.O., functional conformations). This material is based
370 upon work supported by the National Science Foundation Graduate Research Fellowship Program
371 to J.L.O. under Grant No. 1450681. The work was also supported by funds from the National
372 Institutes of Health grants R01 GM117342-0404. Funding and support are also acknowledged
373 from the National Institutes of Health grant R01 GM095583, from the Biodesign Center for
374 Applied Structural Discovery at ASU, from the National Science Foundation award No. 1565180,
375 and the U.S. Department of Energy through Lawrence Livermore National Laboratory under
376 contract DE-AC52-07NA27344. K. A. Z. was supported by the Cornell Molecular Biophysics
377 Training Program (NIH T32-GM008267). This work was also supported by the Cluster of
378 Excellence “CUI: Advanced Imaging of Matter” of the Deutsche Forschungsgemeinschaft (DFG)
379 - EXC 2056 - project ID 390715994. CFEL is supported by the Gottfried Wilhelm Leibniz Program
380 of the DFG; the project “X-probe” funded by the European Union’s 2020 Research and Innovation
381 Program under the Marie Skłodowska-Curie grant agreement 637295; the European Research
382 Council, “Frontiers in Attosecond X-ray Science: Imaging and Spectroscopy (AXSIS)”, ERC-
383 2013-SyG 609920; and the Human Frontiers Science Program grant RGP0010 2017. This work is
384 also supported by the AXSIS project funded by the European Research Council under the
385 European Union Seventh Framework Program (FP/2007-2013)/ERC Grant Agreement no.
386 609920. The structures and diffraction data of the BlaC, unmixed and mixed with Ceftriaxone at
387 0 s, 5 ms, 10 ms and 50 ms are deposited to the Protein Data Bank (pdb) with the following access
388 codes. CEF: 7K8L (unmixed), 7K8E (5 ms), 7K8F (10 ms), 7K8H (50 ms), SUB: 7K8K (66 ms).
389 The SFX stream files were deposited in the CXIDB with code 170.

390

391 **Author Contributions**

392 S.P., T.M., J.M-G., J.H.-Y., F.K., I.P., M.M., R.J., M.S., W.X., J.O. expressed, purified and
393 crystallized the protein. R.B., K.D., H.K., M.K., J.K., G.M., T.S., M.V. operated the SPB/SFX
394 instrument. L.P., A.M.K, G.C., K.A.Z. designed and provided injector nozzles. M.V., F. K., M.K.

395 assembled and operated the nozzles, F.K., J.M-G., J-H.Y., L.G., P.S., collected the data. S.P., I.P.,
396 O.Y., V.M., P.S., A.T., A.B. processed the data. S.P., I.P., T.M., G.P. M.S. analyzed the data. I.P.,
397 M.F., A.S., F.K., P.S., M.S. logged the experiment. R.B., A.P.M., M.S.,G.P. designed the
398 experiment. S.P., P.F., A.P.M., R.B., G.P., M.S. wrote the manuscript with input from all other
399 authors.

400

401 **Supplementary Materials.**

402 **(The Supplementary Material is available from the authors on request)**

403

404 Materials and Methods

405 References 40 - 49

406 Schemes S1 to S2

407 Figs. S1 to S2

408 Tables S1 to S5

409

410 **Other Supplementary Material for this manuscript includes the following:**

411 movie_1

412

413

414

415

416

417

418

419

421

422

423

424

425